Selank: separating real anxiolytic data from peptide hype

What did @jts.p3ps actually say?

The creator described Selank as "a brain peptide that modulates GABA" and drew a direct comparison to alcohol and benzodiazepines, both of which act on GABA-A receptors. Their core claim is that Selank works differently. They called it a GABA "modulator" rather than a GABA-A agonist, and said this distinction explains why users report feeling "relaxed but functional" without the brain fog associated with benzos or alcohol.

That framing is doing a lot of work. The creator is implying Selank produces anxiolytic effects through a cleaner, more selective mechanism. That is a real scientific claim, not just a vibe. Let us look at whether the evidence actually supports it.

Does the science back this up?

Partially, yes. The GABAergic mechanism for Selank has legitimate preclinical support, but the human evidence is thin and the mechanism is more complicated than the video suggests.

Selank is a synthetic heptapeptide analogue of tuftsin, originally developed at the Institute of Molecular Genetics in Moscow. Russian-language literature, including work by Semenova et al. (2010, CNS Neuroscience and Therapeutics), reported anxiolytic effects in animal models and some early human trials. The researchers noted Selank appeared to influence GABA-A receptor sensitivity and also modulated enkephalins, serotonin, and BDNF pathways. That last part matters: Selank's mechanism is not cleanly GABA-centric. It appears to be a broader neuromodulator.

Zozulya et al. (2001, Bulletin of Experimental Biology and Medicine) documented anxiolytic effects in rats without sedation at standard doses. That aligns with the "clear and calm" user experience the creator describes. But rodent data is not human data, and the peer-reviewed English-language human trial database for Selank is sparse.

What did they get wrong (or right)?

The biggest factual error: calling alcohol and benzodiazepines "GABA-A antagonists." They are not. They are GABA-A positive allosteric modulators. An antagonist blocks a receptor. Benzos and alcohol enhance GABA-A activity. The creator likely meant to say "agonists" or "modulators," but used the wrong term entirely. That is a meaningful distinction in pharmacology and it should not be glossed over.

What they got right is the core observation that Selank does not appear to act as a direct GABA-A agonist the way diazepam does. The preclinical literature supports a more modulatory, indirect interaction with the GABAergic system. The experiential claim, that users report clarity alongside relaxation, is consistent with reported subjective effects in small studies and user-reported data, though that is not the same as clinical proof.

• Wrong: calling benzos and alcohol "GABA-A antagonists"
• Right: Selank appears to work differently from direct GABA-A agonists
• Oversimplified: describing Selank as primarily a GABA modulator, when serotonin, BDNF, and enkephalin pathways are also implicated

What should you actually know?

Selank is not approved by the FDA. It is available in Russia as a registered anxiolytic nasal spray, but in the United States it exists in a regulatory gray zone, sometimes compounded and sold for research purposes. That matters if you are considering it.

The "relaxed but functional" framing is plausible based on limited evidence, but it is not settled science. The human trials that exist are small, often Russian-language, and not replicated in large Western double-blind controlled studies. Comparing Selank favorably to benzodiazepines in a short TikTok without those caveats gives viewers a false sense of certainty about a peptide with a thin clinical dossier.

If anxiety is what you are trying to address, that conversation belongs with a licensed clinician who can weigh your history, your current medications, and the actual evidence base. Selank may be interesting. It is not proven.